Mild Cognitive Impairment Market Size was ~USD 2,836 million in 2023 and is Expected to grow rapidly by 2034

The Mild Cognitive Impairment market size was valued ~USD 2,836 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Mild Cognitive Impairment landscape.

In 2023, the United States represented the largest share of the Mild Cognitive Impairment market within the 7MM, contributing roughly 52% of the total market value. In comparison, among the EU4 countries and the United Kingdom, Germany recorded the highest market size at USD 222 million, whereas the UK reported the lowest at approximately USD 88 million. Japan’s Mild Cognitive Impairment market was valued at around USD 670 million in 2023.

DelveInsight’s analysis indicates that in 2023, the United States recorded approximately 1.21 million diagnosed prevalent cases of Parkinson’s disease. Within Europe, Germany reported the highest number of diagnosed prevalent Alzheimer’s disease cases at around 1.49 million, followed by France with roughly 1.17 million cases. In contrast, the United Kingdom had the smallest prevalent population, with about 620,000 cases.

In Japan, there were approximately 2.73 million diagnosed cases of Mild Cognitive Impairment in 2024, including around 103,000 cases linked to Parkinson’s disease and 2.627 million cases associated with Alzheimer’s disease. Forecasts indicate that by 2034, Alzheimer’s-related Mild Cognitive Impairment will continue to rise, surpassing Parkinson’s-related cases, emphasizing the growing impact of Alzheimer’s on the aging population.

According to DelveInsight’s analysis, the United States recorded the highest number of diagnosed prevalent Mild Cognitive Impairment cases among the 7MM, totaling approximately 4.22 million in 2023. Projections suggest that the United Kingdom will maintain a leading position in these cases by 2034. In the same year, around 6.98 million individuals in the US were affected by Alzheimer’s disease, representing the largest case count within the 7MM. These numbers are expected to rise further by 2034.

DelveInsight’s report, “Mild Cognitive Impairment Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Mild Cognitive Impairment landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. 

Additionally, it examines Mild Cognitive Impairment market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Mild Cognitive Impairment market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mild Cognitive Impairment Market Forecast

Some of the key facts of the Mild Cognitive Impairment Market Report:

• With the expected launch of upcoming therapies, such as Valiltramiprosate, Mirodenafil, and Hydromethylthionine mesylate (HMTM), among others, the total market size of Mild Cognitive Impairment is expected to show change in the upcoming years.
• In Mild Cognitive Impairment, approved treatments like LEQEMBI (lecanemab-irmb) and KISUNLA (donanemab-azbt) focus on Alzheimer’s-related cases, while pipeline therapies such as AGB101 and TRx0237 are being developed to expand available treatment options.
• Key Mild Cognitive Impairment Companies: AgeneBio, TauRx Pharmaceuticals, Oligomerix, FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
• Key Mild Cognitive Impairment Therapies: AGB101, TRx0237/Hydromethylthionine Mesylate (HMTM), OLX-07010, T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others
• The Mild Cognitive Impairment market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Cognitive Impairment pipeline products will significantly revolutionize the Mild Cognitive Impairment market dynamics. 

Mild Cognitive Impairment Overview

Mild Cognitive Impairment (MCI) is a condition characterized by noticeable problems with memory, thinking, or concentration that are greater than expected for a person’s age but not severe enough to significantly interfere with daily activities or independence.
Individuals with MCI may forget conversations, misplace items, struggle to focus, or have difficulty making decisions, while still performing routine tasks like managing finances or self-care. MCI may remain stable, improve, or progress to more serious disorders such as Alzheimer’s disease, making early detection and monitoring important.

Get a Free sample for the Mild Cognitive Impairment Market Report:

https://www.delveinsight.com/report-store/mild-cognitive-impairment-market

Key Trends in Mild Cognitive Impairment Therapeutics Market:

• Increasing Focus on Early Diagnosis and Intervention: Growing awareness of the importance of early cognitive screening and biomarker-based assessment is driving earlier detection and treatment before progression to dementia or Alzheimer’s disease.
• Emergence of Disease-Modifying Therapies: The approval and development of anti-amyloid therapies such as LEQEMBI and KISUNLA and research into tau-targeted molecules are shifting treatment beyond symptomatic relief toward slowing disease progression.
• Integration of Digital Therapeutics and Cognitive Training Tools: AI-based cognitive assessment platforms, digital cognitive training programs, and remote monitoring technologies are gaining adoption as complementary or standalone options to support cognitive function improvement.
• Growing Use of Biomarkers and Advanced Imaging: PET imaging, CSF biomarkers, and blood-based biomarkers are increasingly used to stratify patients, monitor disease progression, and support precision-based therapy selection.
• Expanding Clinical Pipeline and Investment Activity: Robust R&D efforts featuring therapies such as neuroprotective agents, synaptic enhancers, and metabolic pathway modulators indicate strong innovation and rising pharmaceutical and biotech investment in the MCI landscape.

Mild Cognitive Impairment Epidemiology

The Mild Cognitive Impairment epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mild Cognitive Impairment Epidemiology Segmentation:

The Mild Cognitive Impairment market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Mild Cognitive Impairment in the 7MM
• Subtype-specific Cases of Mild Cognitive Impairment in the 7MM
• Age-specific Cases of Mild Cognitive Impairment in the 7MM
• Total Diagnosed Prevalent Cases of Mild Cognitive Impairment in the 7MM
• Associated Disease-specific Cases of Mild Cognitive Impairment in the 7MM
• Treated Cases of Mild Cognitive Impairment in the 7MM

Download the report to understand which factors are driving Mild Cognitive Impairment epidemiology trends @ Mild Cognitive Impairment Epidemiology Forecast

Recent Development In The Mild Cognitive Impairment Treatment Landscape:

• In April 2025, At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Alzheon shared findings from its Phase III APOLLOE4 (NCT04770220) trial during a company-sponsored symposium. The study evaluated ALZ-801 (valiltramiprosate), an oral small molecule that blocks the formation of neurotoxic amyloid beta (Aβ) oligomers, in patients with early-stage Alzheimer’s disease—specifically those with mild cognitive impairment (MCI) or mild Alzheimer’s—who are homozygous carriers of the APOE4 gene.
• In December 2024, Blarcamesine (ANAVEX2-73) has been accepted for review by the EMA for the treatment of Alzheimer’s disease. This submission was supported by positive findings from the ANAVEX2-73-AD-004 clinical trial, which involved patients in the early stages of Alzheimer’s.
• As of December 2024, TauRx is actively engaging with the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) concerning its UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet aimed at treating mild cognitive impairment due to Alzheimer's (MCI-AD) and mild to moderate Alzheimer’s disease.
• In July 2024, The US FDA has granted approval to KISUNLA (donanemab-azbt, 350 mg/20 mL), an Alzheimer's treatment developed by Eli Lilly. The therapy is intended for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment (MCI) and mild dementia confirmed to have amyloid pathology.
• In October 2024, AgeneBio reported that its Phase 2B trial of AGB101 showed a 40% reduction in clinical decline and notable slowing of entorhinal cortex atrophy in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease who are non-carriers of the ApoE-4 allele, compared to placebo. The ongoing findings from the HOPE4MCI trial strongly support continued evaluation of AGB101 in this specific patient group. The company is currently conducting an extension of the study in the US (NCT05986721).

Mild Cognitive Impairment Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mild Cognitive Impairment market or expected to get launched during the study period. The analysis covers Mild Cognitive Impairment market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mild Cognitive Impairment Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mild Cognitive Impairment Therapies and Key Companies

• AGB101: AgeneBio
• TRx0237/Hydromethylthionine Mesylate (HMTM): TauRx Pharmaceuticals
• OLX-07010: Oligomerix
• LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
• KISUNLA (Donanemab): Eli Lilly and Company
• Valiltramiprosate (ALZ-801): Alzheon Inc.
• Mirodenafil (AR1001): AriBio Co., Ltd.
• Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics
• T-817MA: FUJIFILM Toyama Chemical Co. Ltd.
• NYX-458: Aptinyx
• Aptinyx: AgeneBio
• T-817MA: FUJIFILM Toyama Chemical Co., Ltd.
• Aricept (donepezil hydrochloride): Eisai Inc.
• CX516: RespireRx
• AL-208: Allon Therapeutics
• CST-2032: CuraSen Therapeutics, Inc.
• ladostigil hemitartrate: Avraham Pharma
• AZD5213: AstraZeneca
• SAGE-718: Sage Therapeutics
• fesoterodine: Pfizer
• MMH-MAP: Materia Medica Holding
• Donanemab: Eli Lilly and Company
• Flutemetamol (18F) Injection: GE Healthcare
• EVP-0962: Parexel

Discover more about therapies set to grab major Mild Cognitive Impairment market share @ Mild Cognitive Impairment Treatment Market

Mild Cognitive Impairment Market Drivers

• Increasing prevalence of MCI and aging populations worldwide, raising demand for effective therapies.
• Growing awareness among clinicians and caregivers about early diagnosis and intervention.
• Advancements in diagnostic technologies, including biomarkers, neuroimaging, and cognitive assessment tools.
• Development of novel therapeutics targeting cognitive decline and neuroprotection.
• Supportive regulatory frameworks and orphan drug incentives promoting R&D in neurodegenerative conditions.

Mild Cognitive Impairment Market Barriers

• High cost of advanced diagnostic tools and therapies, limiting accessibility for some patients.
• Variability in disease progression and symptoms, complicating treatment standardization.
• Limited awareness in certain regions, leading to underdiagnosis or delayed diagnosis.
• Challenges in demonstrating clinical efficacy in early-stage cognitive disorders for regulatory approval.
• Patient adherence and long-term monitoring issues, affecting real-world treatment outcomes.

Scope of the Mild Cognitive Impairment Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Mild Cognitive Impairment Companies: AgeneBio, TauRx Pharmaceuticals, Oligomerix, FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
• Key Mild Cognitive Impairment Therapies: AGB101, TRx0237/Hydromethylthionine Mesylate (HMTM), OLX-07010, T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others
• Mild Cognitive Impairment Therapeutic Assessment: Mild Cognitive Impairment current marketed and Mild Cognitive Impairment emerging therapies
• Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment market drivers and Mild Cognitive Impairment market barriers
• Mild Cognitive Impairment Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Mild Cognitive Impairment Unmet Needs, KOL’s views, Analyst’s views, Mild Cognitive Impairment Market Access and Reimbursement  

To know more about Mild Cognitive Impairment companies working in the treatment market, visit @ Mild Cognitive Impairment Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.